$NXTC News

NextCure Provides Business Update and Reports Second Quarter 2026 Financial Results

NextCure Q2 EPS $(2.80) Misses $(1.94) Estimate

Nextcure Transforms Into Avere as Investors Back Oral Psoriasis Therapy

NextCure and Avere Therapeutics Announce Merger to Advance Once-Weekly Oral IL-23 Therapy

NXTC Announces Replay Available for Virtual KOL Event Discussing ASCO 2026 Dose Escalation Data from Phase 1 Trial of SIM0505 for Gynecologic Cancers

What's Going On With NextCure Stock Wednesday?

NextCure, Inc. (NXTC) Discusses Preliminary Phase I Data for SIM0505 in Platinum-Resistant Ovarian Cancer and Uterine Serous Carcinoma Transcript

NextCure, Inc. (NXTC) Discusses Preliminary Phase I Data for SIM0505 in Platinum-Resistant Ovarian Cancer and Uterine Serous Carcinoma - Slideshow

NextCure Presents Positive SIM0505 Phase 1 Dose Escalation Data in Patients with Gynecologic Cancers at ASCO 2026

NextCure, Simcere Zaiming Pharmaceutical Present Phase 1 Dose Escalation Data For SIM0505 At American Society For Clinical Oncology With Proprietary Topoisomerase 1 Inhibitor Payload

LUCID CAPITAL MARKETS Initiates Coverage On NextCure with Buy Rating, Announces Price Target of $25

NextCure Provides Business Update and Reports First Quarter 2026 Financial Results

NextCure Q1 EPS $(1.87) Beats $(2.12) Estimate

NextCure and Simcere Zaiming Initiate Dose Optimization for SIM0505 (CDH6 ADC) in Gynecologic Cancers

NextCure and Simcere’s SIM0505 (CDH6 ADC) Phase 1 Data to be Presented at ASCO 2026

NextCure And Simcere Zaiming Announce Phase 1 Data For SIM0505 In Treatment Of Solid Tumors Will Be Presented At ASCO 2026

NextCure Receives Fast Track Designation for SIM0505 (CDH6 ADC) in Ovarian Cancer

NextCure's SIM0505 Receives FDA Fast Track For Platinum-Resistant Ovarian Cancer, Phase 1 Data To Be Presented At ASCO 2026

NextCure and Simcere’s SIM0505 (CDH6 ADC) Abstract Accepted for ASCO 2026

NextCure Provides Business Update and Reports Full Year 2025 Financial Results